Clinical Ovarian Cancer & Other Gynecologic Malignancies

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
  • In the cohort of patients with gynecologic tumors, the RECIST response was 50%, OR was 60%, and CBR was 70%.
  • These patients also had a median of 3 and up to 9 prior lines of therapy, before administration of lunresertib.
  • RP-3467 is Repare’s wholly-owned Polθ inhibitor, currently in IND-enabling studies, which began in the second quarter of 2023 and remain ongoing.

Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Retrieved on: 
Monday, November 6, 2023

“Azenosertib continues to show very encouraging monotherapy anti-tumor activity, safety and tolerability in both ovarian cancer and uterine serous carcinoma.

Key Points: 
  • “Azenosertib continues to show very encouraging monotherapy anti-tumor activity, safety and tolerability in both ovarian cancer and uterine serous carcinoma.
  • Zentalis is the only company known to have both a WEE1 inhibitor, azenosertib, and a BCL-2 inhibitor, ZN-d5, in clinical development.
  • Research and Development Expenses: Research and development (R&D) expenses for the quarter ended September 30, 2023 were $46.8 million, compared to $42.2 million for the quarter ended September 30, 2022.
  • General and Administrative Expenses: General and administrative (G&A) expenses for the quarter ended September 30, 2023 were $16.0 million, compared to $12.0 million during the quarter ended September 30, 2022.

Florida Cancer Specialists & Research Institute Announces Bradley Monk, MD as Medical Director of Late-Phase Clinical Research Program

Retrieved on: 
Tuesday, October 10, 2023

FORT MYERS, Fla., Oct. 10, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that Bradley Monk, MD will join the statewide practice as Medical Director of Late-Phase Research, effective January 1, 2024.

Key Points: 
  • FORT MYERS, Fla., Oct. 10, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that Bradley Monk, MD will join the statewide practice as Medical Director of Late-Phase Research, effective January 1, 2024.
  • Bradley Monk, MD to join FCS as Medical Director of Late-Phase Clinical Research in January 2024.
  • Board-certified in gynecologic oncology and obstetrics and gynecology, Dr. Monk joins FCS with extensive experience in clinical research and the development of clinical research programs in community oncology settings.
  • "The research and innovation coming out of FCS is paving the way for the next generation of medical oncologists and hematologists.

Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023.
  • In April 2023, we received a payment of $4 million from Roche for additional revisions to the clinical development plan under the Roche Agreement.
  • The article, entitled “Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results” can be accessed here .
  • Second Quarter 2023 Financial Results:
    Cash and cash equivalents and marketable securities: Cash and cash equivalents and marketable securities as of June 30, 2023 were $280.7 million, which Repare believes will be sufficient to fund its planned operations into 2026.

Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

Retrieved on: 
Wednesday, August 9, 2023

NEW YORK and SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the quarter ended June 30, 2023, and highlighted recent corporate accomplishments.

Key Points: 
  • Azenosertib plus chemotherapy combinations also demonstrated positive results in women facing heavily pretreated ovarian cancer.
  • Presented positive azenosertib + chemotherapy combination data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Zentalis is preparing for a Phase 3 trial of azenosertib using intermittent dosing in combination with chemotherapy in Cyclin E1+ platinum-sensitive ovarian cancer.
  • Cash and Marketable Securities Position: As of June 30, 2023, Zentalis had cash, cash equivalents and marketable securities of $553.0 million.

Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer

Retrieved on: 
Tuesday, August 1, 2023

NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Kimberly Freeman as Chief Strategy Officer.

Key Points: 
  • NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Kimberly Freeman as Chief Strategy Officer.
  • In this role, she will support and implement Zentalis’ long-term portfolio strategy.
  • Ms. Freeman joins Zentalis with over 25 years of clinical development and strategic leadership experience, including deep expertise in oncology, particularly in gynecologic malignancies and the DNA damage response (DDR) pathway.
  • “Kimberly brings an outstanding track record of building and executing drug development and franchise strategies that will be invaluable to Zentalis as we seek to capitalize on the significant opportunity we see with azenosertib across a broad array of tumor types,” said Dr. Kimberly Blackwell, Chief Executive Officer of Zentalis.

Burjeel Medical City Launches Advanced Gynecology Institute to Offer Complex Care Solutions for Women

Retrieved on: 
Tuesday, May 23, 2023

Burjeel Medical City, the flagship facility of Burjeel Holdings, has launched an Advanced Gynecology Institute (AGI) designed to offer multidisciplinary healthcare solutions to women of all ages.

Key Points: 
  • Burjeel Medical City, the flagship facility of Burjeel Holdings, has launched an Advanced Gynecology Institute (AGI) designed to offer multidisciplinary healthcare solutions to women of all ages.
  • Three specialized clinics of the hospital - Gynecological Oncology, IFEM Endo Middle East Clinic, and Complex Gynecology Care - will come under AGI.
  • Dr. Maitha Bint Salem Al Shamsi, Minister of State, UAE Government, inaugurating Advanced Gynecology Institute at Burjeel Medical City (Photo: AETOSWire)
    Prof. Horace Roman, a renowned endometriosis surgeon and founding member of IFEM Endo, will be heading the institute.
  • “The institute showcases our commitment to excellence and cements our position as a leader in complex care.

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, March 28, 2023

LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the year ended December 31, 2022 and provided an update on recent corporate highlights.

Key Points: 
  • LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the year ended December 31, 2022 and provided an update on recent corporate highlights.
  • “In 2022, we made important progress in the ongoing advancement of our core rare disease programs.
  • Full year 2022 research and development expenses were £25.0 million, compared to £23.6 million, in 2021, an increase of £1.4 million, or 6%.
  • Total ADSs outstanding at December 31, 2022 were approximately 119 million, with each ADS representing five ordinary shares of the Company.

Huichao Liang, An Expert on AIDS Combined with Gynecological Oncology, Receives Excellent Popular Science Worker Award

Retrieved on: 
Friday, February 24, 2023

Among gynecological tumors, cervical cancer, endometrial cancer and ovarian cancer are still the most important female reproductive system malignancies threatening women's health.

Key Points: 
  • Among gynecological tumors, cervical cancer, endometrial cancer and ovarian cancer are still the most important female reproductive system malignancies threatening women's health.
  • How to improve the survival rate and cure rate of gynecological tumor patients is the focus of research of gynecological oncology experts at home and abroad.
  • Huichao Liang spent a lot of time and energy on the integration and improvement of the medical team.
  • As an infectious disease combined with gynecological oncology expert, Huichao Liang must face the terrible viruses and bacteria and defeat them with wisdom.

Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer

Retrieved on: 
Friday, February 10, 2023

The VB-C-04 trial will evaluate the combination therapies in patients with cervical cancer that have progressed following first line treatment.

Key Points: 
  • The VB-C-04 trial will evaluate the combination therapies in patients with cervical cancer that have progressed following first line treatment.
  • Nykode has previously reported positive interim data from the Phase 2 VB-C-02 trial in Europe in patients with heavily pre-treated advanced cervical cancer.
  • VB10.16, wholly owned by Nykode, is a potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate in development for the treatment of HPV16-positive cancers.
  • “We are thrilled to partner with Nykode Therapeutics to conduct VB-C-04, a ground-breaking study to investigate Nykode’s therapeutic cancer vaccine candidate for the treatment of patients with advanced cervical cancer.